Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NSPR InspireMD	$2.52 -2.3%	$2.42	$1.99 ▼ $3.80	$105.14M	0.6	102,985 shs	58,136 shs
NTRB Nutriband	$6.80 -0.7%	$7.90	$3.72 ▼ $11.78	$76.41M	1.13	194,285 shs	70,584 shs
NXGL NexGel	$2.71 +2.3%	$2.48	$2.10 ▼ $5.10	$20.28M	0.57	57,672 shs	50,605 shs
TELA TELA Bio	$1.60 -14.0%	$1.88	$0.86 ▼ $3.39	$73.57M	0.93	66,942 shs	282,004 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NSPR InspireMD	+6.61%	-3.37%	+9.32%	+6.17%	-9.79%
NTRB Nutriband	-4.46%	-3.66%	-13.94%	+19.55%	+25.69%
NXGL NexGel	-1.49%	+1.92%	+0.95%	-3.99%	-7.34%
TELA TELA Bio	+8.14%	+0.54%	-7.00%	+89.80%	-54.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NSPR InspireMD	3.0239 of 5 stars	3.5	3.0	1.1	4.2	0.6
NTRB Nutriband	3.2216 of 5 stars	3.5	5.0	2.3	1.7	0.6
NXGL NexGel	1.0392 of 5 stars	0.0	4.0	2.5	2.5	0.0
TELA TELA Bio	2.778 of 5 stars	3.4	4.0	2.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NSPR InspireMD	3.00	Buy	$4.50	78.57% Upside
NTRB Nutriband	3.00	Buy	$13.00	91.18% Upside
NXGL NexGel	0.00	N/A	N/A	N/A
TELA TELA Bio	2.75	Moderate Buy	$7.25	353.13% Upside

Current Analyst Ratings Breakdown

Latest NXGL, NTRB, NSPR, and TELA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/12/2025	NSPR InspireMD	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$4.50 ➝ $4.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NSPR InspireMD	$7.07M	14.88	N/A	N/A	$1.83 per share	1.38
NTRB Nutriband	$2.14M	35.43	N/A	N/A	$0.58 per share	11.72
NXGL NexGel	$8.69M	2.39	N/A	N/A	$0.90 per share	3.01
TELA TELA Bio	$69.30M	0.91	N/A	N/A	$0.72 per share	2.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NSPR InspireMD	-$19.92M	-$0.83	N/A	N/A	N/A	-413.96%	-69.42%	-57.68%	N/A
NTRB Nutriband	-$10.48M	-$0.90	N/A	N/A	N/A	-415.93%	-68.25%	-60.40%	9/2/2025 (Estimated)
NXGL NexGel	-$3.28M	-$0.45	N/A	∞	N/A	-30.80%	-54.95%	-27.84%	8/12/2025 (Estimated)
TELA TELA Bio	-$37.84M	-$1.41	N/A	N/A	N/A	-54.12%	-303.41%	-56.40%	N/A

Latest NXGL, NTRB, NSPR, and TELA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2025	N/A	NTRB Nutriband	-$0.17	N/A	N/A	N/A	$0.71 million	N/A
8/12/2025	Q2 2025	NXGL NexGel	-$0.07	-$0.09	-$0.02	-$0.09	$3.08 million	N/A
8/11/2025	Q2 2025	TELA TELA Bio	-$0.18	-$0.22	-$0.04	-$0.22	$20.67 million	$20.20 million
5/30/2025	Q1 2026	NTRB Nutriband	-$0.13	-$0.12	+$0.01	-$0.12	$0.71 million	$0.67 million
5/13/2025	Q1 2025	NXGL NexGel	-$0.10	-$0.09	+$0.01	-$0.09	$2.73 million	$2.81 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NSPR InspireMD	N/A	N/A	N/A	N/A	N/A
NTRB Nutriband	N/A	N/A	N/A	N/A	N/A
NXGL NexGel	N/A	N/A	N/A	N/A	N/A
TELA TELA Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NSPR InspireMD	N/A	6.39	6.05
NTRB Nutriband	0.01	3.71	3.48
NXGL NexGel	0.15	1.88	1.15
TELA TELA Bio	2.28	4.22	3.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NSPR InspireMD	44.78%
NTRB Nutriband	19.70%
NXGL NexGel	2.21%
TELA TELA Bio	94.35%

Insider Ownership

Company	Insider Ownership
NSPR InspireMD	34.06%
NTRB Nutriband	54.09%
NXGL NexGel	20.55%
TELA TELA Bio	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NSPR InspireMD	50	41.72 million	18.33 million	Optionable
NTRB Nutriband	10	11.15 million	5.12 million	Not Optionable
NXGL NexGel	10	7.65 million	6.08 million	Not Optionable
TELA TELA Bio	120	39.56 million	37.70 million	Optionable

NXGL, NTRB, NSPR, and TELA Headlines

Recent News About These Companies

TELA Bio (NASDAQ:TELA) Issues Earnings Results

2 hours ago | marketbeat.com

Tela Bio backs FY25 revenue view $85M-$88M, consensus $86.05M

August 12 at 2:33 AM | msn.com

Tela Bio reiterates $85M–$88M 2025 revenue target as international expansion accelerates

August 12 at 2:33 AM | msn.com

TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates

August 11 at 8:06 PM | zacks.com

TELA Bio, Inc. (TELA) Q2 2025 Earnings Call Transcript

August 11 at 8:04 PM | seekingalpha.com

TELA Bio Reports Second Quarter 2025 Financial Results

August 11 at 4:03 PM | globenewswire.com

TELA Bio Inc (TELA) Q2 2025 Earnings Report Preview: What To Expect

August 10 at 1:37 PM | finance.yahoo.com

TELA Bio Awards Inducement Equity Grants to New Employees

August 10 at 8:36 AM | msn.com

TELA Bio (TELA) Projected to Post Earnings on Monday

August 9 at 2:43 AM | americanbankingnews.com

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 8, 2025 | globenewswire.com

TELA Bio (TELA) Expected to Announce Quarterly Earnings on Monday

August 5, 2025 | marketbeat.com

TELA Bio (NASDAQ:TELA) Trading 4.2% Higher - Time to Buy?

July 30, 2025 | marketbeat.com

TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Conference

July 23, 2025 | globenewswire.com

AIGH Capital Management LLC Sells 1,246,462 Shares of TELA Bio, Inc. (NASDAQ:TELA)

July 22, 2025 | marketbeat.com

TELA Bio to Announce Second Quarter 2025 Financial Results

July 21, 2025 | globenewswire.com

TELA Bio, Inc. (TELA) Latest Stock News & Headlines - Yahoo Finance

July 19, 2025 | finance.yahoo.com

Breakeven On The Horizon For TELA Bio, Inc. (NASDAQ:TELA)

July 3, 2025 | finance.yahoo.com

TELA Bio Welcomes Jim Hagen with Strategic Equity Grant

June 9, 2025 | msn.com

TELA Bio, Inc.: TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 7, 2025 | finanznachrichten.de

TELA Bio, Inc. Grants Inducement Equity Awards to New Senior Vice President Jim Hagen

June 6, 2025 | quiverquant.comQ

TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXGL, NTRB, NSPR, and TELA Company Descriptions

InspireMD NYSE:NSPR

$2.52 -0.06 (-2.33%)

Closing price 04:00 PM Eastern

Extended Trading

$2.58 +0.06 (+2.38%)

As of 06:12 PM Eastern

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

Nutriband NASDAQ:NTRB

$6.80 -0.05 (-0.73%)

Closing price 04:00 PM Eastern

Extended Trading

$6.67 -0.13 (-1.91%)

As of 07:57 PM Eastern

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

NexGel NASDAQ:NXGL

$2.71 +0.06 (+2.26%)

Closing price 03:59 PM Eastern

Extended Trading

$2.61 -0.10 (-3.65%)

As of 06:35 PM Eastern

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.

TELA Bio NASDAQ:TELA

$1.60 -0.26 (-13.98%)

Closing price 04:00 PM Eastern

Extended Trading

$1.51 -0.09 (-5.63%)

As of 06:03 PM Eastern

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time